-
COVID-19 POLICY PAPERS »
-
Fewer new drug approvals in Canada: consequences from new PMPRB rules »
-
Patented Medicines Costs of Private Insurers: PMPRB Implications »
-
New Patented Medicine Regulations will limit access to drugs for rare disorders. »
-
Potential impact of U.S. demand on the Canadian supply of 46 prescription drugs. »
-
Coverage of new medicines in Federal-Provincial public drug plans 2009-2018 »
-
Coverage of new medicines in private versus public drug plans in Canada 2009-2018. »
-
Patented drug prices and clinical trials in 31 OECD countries 2017: implications for Canada’s PMPRB. »
-
Medical resources and spending across provincial healthcare systems in Canada. »
-
HTA and public coverage of new mental health drugs in Quebec and Canada. »
-
Medical Resources in Canada and OECD countries. »
-
Evidence that innovative medicines improve health and economic outcomes. »
-
Close the Gaps: Patient Benefits and Taxpayer Costs of 3 Pharmacare Options. »
-
Pan-Canadian Pharmaceutical Alliance negotiations 2014-2018. »
-
Facts about the cost of patented drugs in Canada: 2018 Edition. »
-
VIDEO - National Pharmacare Facts. »
-
Out-of-pocket prescription drug costs: What are the implications for National Pharmacare? »
-
How much will National Pharmacare cost taxpayers? »
-
Is Canada under-investing in the use of medical devices? »
-
Who needs pharmacare? All Canadians are covered under existing private and public drug plans. »
-
Expertise gaps on Canada’s HTA advisory committees »
-
Consequences of over-regulating the prices of new drugs in Canada »
-
Costs without benefits for patients? Non-medical spending in Canada’s public health system »
-
Does Canada need a Patented Medicine Prices Review Board? »
-
The fiscal burden of provincial government health spending across Canada »
-
Abuse deterrent formulations for all prescription opioids could save $billions in societal costs »
-
Hospital spending compared across Canada’s Provinces »
-
HTA and delays to accessing mental health drugs in Canada »
-
Fewer treatment options for patients if Canada adopts New Zealand's prescription drug policies »
-
Governments could save $5 billion annually by allowing modest user charges for physician services »
-
How long do new patented medicines have market exclusivity in Canada’s public drug plans? »
-
What is the cost of physicians across Canada by province? »
-
Economic cost of lost health gains from delayed access to 14 new cancer drugs. »
-
Capturing value for patients: HTA and the utility-expansion of new cancer drugs. »
Latest
-
Evidence that regulating pharmaceutical prices negatively affects R&D and access to new medicines.
A systematic literature review. Yanick Labrie, MSc. »
-
COVID-19 Economic Costs and the Implicit Value of a Life-Year in Canada.
UPDATED Economic value of a life-year implied by the government policy response to COVID-19 exceeds the cost effectiveness thresholds used by CADTH and PMPRB. Brett Skinner, PhD. »
-
A Socio-Psychological Perspective on Flattening the COVID-19 Curve.
Implications for public health program delivery in Canada. Umar Ruhi, PhD. »
-
Did the PMPRB censor CHPI's Submission to its Draft Guidelines Consultation?
Read the paper that the PMPRB omitted. »
-
Clinical Trials in Canada Decrease: A Sign of Uncertainty Regarding Changes to the PMPRB?
More evidence of early impact from upcoming changes to patented medicines price regulations. Nigel Rawson, PhD. »
-
Fewer new drug approvals in Canada: early indication of unintended consequences from new PMPRB regs?
Pending changes to patented medicines price regulations may already be reducing the availability of new drugs in Canada. Nigel Rawson, PhD. »
-
Patented Medicines Costs of Private Insurers: PMPRB Implications.
The government and the insurance industry say the PMPRB needs additional regulatory powers because the prices of patented medicines are causing a sustainability crisis for private insurers in Canada. Is it true? Brett Skinner, PhD. »
-
New Patented Medicine Regulations in Canada: Updated Case Study. (EN/FR)
PMPRB’s draft guidelines will limit access to drugs for rare disorders. »
-
New drug submissions in the United States and Canada 2014-2019: trends and policy implications.
Canada may have passed a tipping point where we are no longer considered a premier jurisdiction to launch new medicines. »
